Joshua Pinto
President & CEO, Director · Neumora Therapeutics, Inc.
- 2025
- Aug 21, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Joshua Pinto files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners X, LLC - $5.00M in NMRA purchases and sales in the last 12 months
- ARCH Venture Partners XII, LLC - $5.00M in NMRA purchases and sales in the last 12 months
- Kristina Burow - $5.00M in NMRA purchases and sales in the last 12 months
- Daljit Singh Aurora - $1.03M in NMRA purchases and sales in the last 12 months
- Paul L. Berns - $34K in NMRA purchases and sales in the last 12 months
- Michael Lee Milligan - $5K in NMRA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Joshua Pinto?
Joshua Pinto is a corporate insider, tracked as President & CEO, Director of Neumora Therapeutics, Inc. (NMRA). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Joshua Pinto submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Joshua Pinto been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($21K) across all tracked filings.
